Published in Medical Letter on the CDC and FDA, July 30th, 2006
These "small molecules" inhibit tumor growth by effectively reducing blood flow to the tumor. The results of the study appear a recent issue of the Journal of the National Cancer Institute.
"This is a novel class of drugs that increases the potential for good, effective treatment for cancer patients with tumors," said Kevin Mayo, PhD, principle investigator and professor of biochemistry, molecular biology and biophysics at the University of Minnesota Medical School.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA